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CLINICAL EXPFuRIENCE WITH PROGESTERONE THERAPY
          －EFFECTS OF LONG TERM USE一
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  At the former symposium we presented our clinical ，experience with SH－582 which had
been used ln patients with prostatic hypertrophy and carcinoma over a period of 3 months
together with histological findings in a srnall number of animals． At this symposium we
are going to present clinical experience in another 17 patients who were treated for about
6months， and the therapeutic effects iエ1 thern are compared with those ill the previous treat一
皿ent． Estimation of therapeutic effects was， as in the previous treatment， based on changes
in subjective syrnptoms and residual urine volume， palpation， cystography， and biopsy of
the prostate and testis． The therapeutic effect of the prolonged treatment with SH－582 was
considered to be very good in 30％， and good in 35％ of the treated patients．
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 Table 2． After treatment．
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Table 3． Age （from 59 to 78 years）．
Decades Number of individuals
  51N60 i ’ 2














  Table 7． lmprovement of residual urine
       in 17 cases．
Table 5． Residual urine volume in 17 cases．















’ Table 6． 17 patients treated with DEPOSTAT
     （SH－582）．
 Dosis 300 mg in twice weekly
Total dose 13．sg 9 cases
      15．0！1 5 ！！
      18．0 11 2 or













Table 8． lmprovement in feeling of residual



























Table l l． Surnmary．
Table 9． lmprovement of rectal palpation
     and cystogram in 17 cases．
1） Effective・・・…n cases （65％）
2） Testicular atrophy
3） lt caused almost slight feeling of residual
 urine in our cases when the agent was
 given over 9 g
Improvement
No changes
Rectal palpation 1 Cystogram
（H一） 6cases 5 cases
（＋） 5 ii 6 rz
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Fig． 7 Fig． 8
症例13の使用前と使用後
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           Fig． 18 Fig． 19     19：前立腺腫瘍治療剤として通常使用されているホンバン250m9（biethylstilbesterol－
      biphosphate）を隔日25回注射して，臨床的には改善をみた患者の生検組織所見である．
      腺腔は拡張状で腺上皮は立方ないし円柱状であり，部位によっては数層の増殖状を呈す
      る所もある．
       原形質は明るく，組織的にはあまり萎縮を感じられない．
      講編驚麟餐旗黛㌦華
           Fig． 20 Fig． 21     20：症例10の睾丸組織で，一部に出血巣をみるが，これは採取時のものと思われる．精細
      胞は比較的密であって，精子形成を認める．
     21：本剤159使用後の同組織所見である．精細胞は概して粗となり，精子形成もごく一部
      にのみ認められる．この所見は本剤による萎縮と考えられる．また，間質組織ははなは
      だ粗となっているが，生検時の肉眼的所見でも弾力性を欠くようで，バラバラになりや
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